Robinson Cano, oh no.
The New York Mets second baseman has been suspended for the entire 2021 season after testing positive for a performance-enhancing drug for the second time in his career, the team confirmed in a press release.
Cano, who will forfeit the $24 million on his salary for the upcoming season, tested positive for the banned substance Stanozolol.
Mets president Sandy Alderson released a statement on the matter:
"We were extremely disappointed to be informed about Robinson’s suspension for violating Major League Baseball’s Joint Drug Prevention and Treatment Program," he said. "The violation is very unfortunate for him, the organization, our fans, and the sport. The Mets fully support MLB’s efforts toward eliminating performance enhancing substances from the game."
He was previously suspended for 82 games on May 15, 2018 as a member of the Seattle Mariners for also violating MLB’s Joint Drug Prevention and Treatment Program, policy after testing positive for furosemide. The Mariners traded Cano to the Mets the following offseason.
The Mets traded for Cano, along with Mariners closer Edwin Diaz, in exchange for Jay Bruce, Anthony Swarzak and prospects Jerred Kelenic and Justin Dunn in what was the first big splash of former GM Brodie Van Wagenen's tenure.
In 49 games this past season, Cano appeared to have a bit of a resurgence. He his .316/.352/.544 with 10 home runs and 30 RBI.
Cano is still under contract through the 2023 season with $48 million owed to him.
This is a developing story.